254 related articles for article (PubMed ID: 28649001)
1. A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (≤16 years) low grade glioma - A final report.
Gnekow AK; Walker DA; Kandels D; Picton S; Giorgio Perilongo ; Grill J; Stokland T; Sandstrom PE; Warmuth-Metz M; Pietsch T; Giangaspero F; Schmidt R; Faldum A; Kilmartin D; De Paoli A; De Salvo GL;
Eur J Cancer; 2017 Aug; 81():206-225. PubMed ID: 28649001
[TBL] [Abstract][Full Text] [Related]
2. [HIT-LGG: effectiveness of carboplatin-vincristine in progressive low-grade gliomas of childhood--an interim report].
Gnekow AK; Kaatsch P; Kortmann R; Wiestler OD
Klin Padiatr; 2000; 212(4):177-84. PubMed ID: 10994547
[TBL] [Abstract][Full Text] [Related]
3. Low grade chiasmatic-hypothalamic glioma-carboplatin and vincristin chemotherapy effectively defers radiotherapy within a comprehensive treatment strategy -- report from the multicenter treatment study for children and adolescents with a low grade glioma -- HIT-LGG 1996 -- of the Society of Pediatric Oncology and Hematology (GPOH).
Gnekow AK; Kortmann RD; Pietsch T; Emser A
Klin Padiatr; 2004; 216(6):331-42. PubMed ID: 15565548
[TBL] [Abstract][Full Text] [Related]
4. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial.
Ladenstein R; Pötschger U; Pearson ADJ; Brock P; Luksch R; Castel V; Yaniv I; Papadakis V; Laureys G; Malis J; Balwierz W; Ruud E; Kogner P; Schroeder H; de Lacerda AF; Beck-Popovic M; Bician P; Garami M; Trahair T; Canete A; Ambros PF; Holmes K; Gaze M; Schreier G; Garaventa A; Vassal G; Michon J; Valteau-Couanet D;
Lancet Oncol; 2017 Apr; 18(4):500-514. PubMed ID: 28259608
[TBL] [Abstract][Full Text] [Related]
5. Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
Parasramka S; Talari G; Rosenfeld M; Guo J; Villano JL
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011773. PubMed ID: 28744879
[TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up of the multicenter, multidisciplinary treatment study HIT-LGG-1996 for low-grade glioma in children and adolescents of the German Speaking Society of Pediatric Oncology and Hematology.
Gnekow AK; Falkenstein F; von Hornstein S; Zwiener I; Berkefeld S; Bison B; Warmuth-Metz M; Driever PH; Soerensen N; Kortmann RD; Pietsch T; Faldum A
Neuro Oncol; 2012 Oct; 14(10):1265-84. PubMed ID: 22942186
[TBL] [Abstract][Full Text] [Related]
7. Rapid COJEC versus standard induction therapies for high-risk neuroblastoma.
Peinemann F; Tushabe DA; van Dalen EC; Berthold F
Cochrane Database Syst Rev; 2015 May; 2015(5):CD010774. PubMed ID: 25989478
[TBL] [Abstract][Full Text] [Related]
8. Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas.
Packer RJ; Ater J; Allen J; Phillips P; Geyer R; Nicholson HS; Jakacki R; Kurczynski E; Needle M; Finlay J; Reaman G; Boyett JM
J Neurosurg; 1997 May; 86(5):747-54. PubMed ID: 9126887
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcomes with intensive induction chemotherapy (carboplatin, bleomycin, vincristine and cisplatin/bleomycin, etoposide and cisplatin) and standard bleomycin, etoposide and cisplatin in poor prognosis germ cell tumours: A randomised phase II trial (ISRCTN53643604).
Cafferty FH; White JD; Shamash J; Hennig I; Stenning SP; Huddart RA;
Eur J Cancer; 2020 Mar; 127():139-149. PubMed ID: 32007714
[TBL] [Abstract][Full Text] [Related]
10. Nonrandomized comparison of neurofibromatosis type 1 and non-neurofibromatosis type 1 children who received carboplatin and vincristine for progressive low-grade glioma: A report from the Children's Oncology Group.
Ater JL; Xia C; Mazewski CM; Booth TN; Freyer DR; Packer RJ; Sposto R; Vezina G; Pollack IF
Cancer; 2016 Jun; 122(12):1928-36. PubMed ID: 27061921
[TBL] [Abstract][Full Text] [Related]
11. Current Salvage Treatment Strategies for Younger Children (<10 y of Age) With Progressive Low-grade Glioma After Initial Chemotherapy in North America: A Web-based Survey.
Moorman B; Barbour M; Huang MA
J Pediatr Hematol Oncol; 2021 Jan; 43(1):e141-e145. PubMed ID: 33235141
[TBL] [Abstract][Full Text] [Related]
12. High-grade glioma in children under 5 years of age: a chemotherapy only approach with the BBSFOP protocol.
Dufour C; Grill J; Lellouch-Tubiana A; Puget S; Chastagner P; Frappaz D; Doz F; Pichon F; Plantaz D; Gentet JC; Raquin MA; Kalifa C
Eur J Cancer; 2006 Nov; 42(17):2939-45. PubMed ID: 16962317
[TBL] [Abstract][Full Text] [Related]
13. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
Goldman JW; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Garassino MC; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Każarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Thiyagarajah P; Jiang H; Paz-Ares L;
Lancet Oncol; 2021 Jan; 22(1):51-65. PubMed ID: 33285097
[TBL] [Abstract][Full Text] [Related]
14. Carboplatin and Etoposide in Heavily Pretreated Patients with Progressive High-Grade Glioma.
Tonder M; Weller M; Eisele G; Roth P
Chemotherapy; 2014; 60(5-6):375-8. PubMed ID: 26496463
[TBL] [Abstract][Full Text] [Related]
15. Differential responsiveness among "high risk" pediatric brain tumors in a pilot study of dose-intensive induction chemotherapy.
Jennings MT; Cmelak A; Johnson MD; Moots PL; Pais R; Shyr Y
Pediatr Blood Cancer; 2004 Jul; 43(1):46-54. PubMed ID: 15170889
[TBL] [Abstract][Full Text] [Related]
16. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
[TBL] [Abstract][Full Text] [Related]
17. Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the International Society of Pediatric Oncology MMT95 study.
Oberlin O; Rey A; Sanchez de Toledo J; Martelli H; Jenney ME; Scopinaro M; Bergeron C; Merks JH; Bouvet N; Ellershaw C; Kelsey A; Spooner D; Stevens MC
J Clin Oncol; 2012 Jul; 30(20):2457-65. PubMed ID: 22665534
[TBL] [Abstract][Full Text] [Related]
18. Proposed therapeutic strategy for adult low-grade glioma based on aggressive tumor resection.
Nitta M; Muragaki Y; Maruyama T; Ikuta S; Komori T; Maebayashi K; Iseki H; Tamura M; Saito T; Okamoto S; Chernov M; Hayashi M; Okada Y
Neurosurg Focus; 2015 Jan; 38(1):E7. PubMed ID: 25599276
[TBL] [Abstract][Full Text] [Related]
19. Carboplatin and vincristine neurotoxicity in the treatment of pediatric low-grade gliomas.
Rosca L; Robert-Boire V; Delisle JF; Samson Y; Perreault S
Pediatr Blood Cancer; 2018 Nov; 65(11):e27351. PubMed ID: 30014595
[TBL] [Abstract][Full Text] [Related]
20. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group.
Geyer JR; Sposto R; Jennings M; Boyett JM; Axtell RA; Breiger D; Broxson E; Donahue B; Finlay JL; Goldwein JW; Heier LA; Johnson D; Mazewski C; Miller DC; Packer R; Puccetti D; Radcliffe J; Tao ML; Shiminski-Maher T;
J Clin Oncol; 2005 Oct; 23(30):7621-31. PubMed ID: 16234523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
